| Chemical Properties | Back Directory | [Boiling point ]
378.6±42.0 °C(Predicted) | [density ]
1.104±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 125 mg/mL (497.37 mM) | [form ]
Solid | [pka]
0.82±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
3-[(2,5-Dimethylphenyl)amino]-1-phenyl-2-propen-1-one functions as CD40-TRAF6 inhibitors. Inhibition of CD40 signalling pathway seems a better way to ameliorate inflammatory diseases, like the inflammation in models of peritonitis and sepsis. | [Biological Activity]
Cell permeable: yes''Primary Target
TRAF6 | [in vivo]
TRAF-STOP inhibitor 6877002 (10 μmol/kg; intraperitoneal injection; once a day; 6 weeks) retards the development of early atherosclerosis and reduces atherosclerotic plaque area in apolipoprotein E-deficient (Apoe-/-) mice[1].
TRAF-STOP inhibitor 6877002 (10 μmol/kg; intraperitoneal injection; once a day; 6 weeks) halts the progression of established atherosclerosis, induces a stable plaque phenotype, reduces macrophage number and proliferation, decreases the size of necrotic cores, reduces the number of neutrophils and T cells, and increases collagen and αSMA+ smooth muscle cell content in atherosclerotic plaques in apolipoprotein E-deficient (Apoe-/-) mice[1].
TRAF-STOP inhibitor 6877002 (10 μmol/kg; administered via recombinant high-density lipoprotein nanoparticles; twice a week; 6 weeks) reduces plaque volume in the aortic root and the number of macrophages in plaques in apolipoprotein E-deficient (Apoe-/-) mice[1]. | Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (22 weeks old), with advanced atherosclerotic lesions already present in the aortic arch to establish an established atherosclerosis model[1]. | | Dosage: | 10 μmol/kg (vehicle: PBS, 0.05% Tween 80, 5% dimethylsulfoxide) | | Administration: | Intraperitoneal injection, once a day, for 6 weeks | | Result: | Halted the progression of established atherosclerosis, reduced the total atherosclerotic plaque area in the aortic arch and aortic root. The atherosclerotic plaques exhibited a stable phenotype with decreased macrophage number and proliferation, smaller necrotic cores, fewer neutrophils and T cells, and increased collagen and αSMA+ smooth muscle cell content. |
| Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (12 weeks old), fed a normal chow diet to establish an atherosclerosis-prone model[1]. | | Dosage: | 10 μmol/kg (vehicle: PBS, 0.05% Tween 80, 5% dimethylsulfoxide) | | Administration: | Intraperitoneal injection, once a day, for 6 weeks | | Result: | Retarded the development of early atherosclerosis, reduced atherosclerotic plaque area in the aortic arch, and the plaques contained fewer macrophages, T cells, and neutrophils. There were no changes in the number of proliferating or apoptotic cells, plaque smooth muscle cell or collagen content. |
| Animal Model: | Male apolipoprotein E-deficient (Apoe-/-) mice (12 weeks old) with atherosclerosis model[1]. | | Dosage: | 10 μmol/kg (packaged in recombinant high-density lipoprotein nanoparticles) | | Administration: | Administered via recombinant high-density lipoprotein nanoparticles, twice a week, for 6 weeks | | Result: | Reduced plaque volume in the aortic root and the number of macrophages in plaques. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|